Study of two drugs for advanced skin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of cutaneous T-cell lymphoma.
- Your disease is measurable and is at stage IB–IVB.
- You have already tried at least one prior treatment (like radiation, retinoids, or chemotherapy) and it didn't help or it stopped working.
- You are able to do daily activities (ECOG 0–2).
- Your blood counts and organ function (like liver, kidney, heart) are within acceptable ranges.
- You are not pregnant or nursing.
- You do not have active infections or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This study tests a chemotherapy combination (aclarubicin plus three other drugs) in patients 60 and older whose cutaneous T-cell lymphoma (a blood cancer affecting the skin) did not respond to previous treatments. The goal is to see if this new combination works better and is safe.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial tests a combination of three drugs for people with peripheral T-cell lymphoma who cannot have intensive chemotherapy. The goal is to see if this treatment works and is safe.
This trial is testing a combination of two targeted drugs – chidamide (an HDAC inhibitor) and golidocitinib (a JAK inhibitor) – for people with peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
Hear when a new Cutaneous T-cell Lymphoma (CTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.